BioBetter Breaks Bottleneck in Cultivated Meat with Tobacco Plants
BioBetter extracts growth factors for scaled cultivated meat production from tobacco plants
FoodTech start-up, BioBetter, Ltd., has assigned a new role for the much-maligned Nicotiana tabacum plant upon discovering it can overcome the greatest hurdle in cultured meat—that of scaled production. Working behind the scenes of the emerging cultured meat industry, BioBetter is repurposing tobacco plants to create the growth factors necessary for the cellular development of cultivated meat. This landmark botanical breakthrough could significantly reduce the cost of cultivated meat and advance it rapidly to scale-up.
No. 1 Cultivated meat challenge
As numerous cultivated meat start-ups move beyond the proof-of-concept phase, they run against one of the biggest challenges facing this budding industry. Developing a scalable and cost-effective production platform to make cultured meat affordable for the mass market has proven to be a primary stumbling block.
Cell-derived meat requires a culture medium composed of a mix of amino acids, nutrients, and—most importantly—growth factors (GF’s) without which cells cannot multiply. Currently, such media are costly due to the complexity of producing GF’s. For example, insulin and transferrin GFs are collected from livestock, making it difficult to obtain large quantities. Some can be attained via fermentation of yeast or bacteria, but those methods require expensive facilities. The purification process also is complicated and expensive.
“The Good Food Institutes determined that approximately a 100-fold reduction in insulin and transferrin costs is required to make cultivated meat economically viable,” explains Dana Yarden, MD, co-founder of BioBetter. “It is estimated that growth factors and cell-culture media can constitute 55 to 95% of the marginal cost in manufacturing cell-based foods.”
Green, animal-free solution
BioBetter harnessed the inherent advantages of tobacco plants by turning them into bioreactors for expression and large-scale production of the proteins. Plant bioreactors use renewable energy and fixate CO2. They are self-forming, self-sustaining, and biodegradable. BioBetter uses open-field plantations to enable fast, efficient, and flexible response to market needs.
“There are multiple advantages to using Nicotiana tabacum as a hardy vector for producing GFs of non-animal origin,” enthuses Amit Yaari, PhD, CEO of BioBetter. “It is an abundant crop that has no place in the food-and-feed chain due to its extremely bitter taste and content of undesirable alkaloids. The global trend for reducing tobacco smoking also is raising concerns among tobacco growers that the crop might eventually become obsolete. Yet the tobacco plant has huge potential to become a key component in the future of food.” Tobacco plants can achieve up to four growth cycles annually and be harvested all year. This translates to more voluminous outputs per square meter of growing space.
BioBetter’s uniqueness lies in refining and highlighting the advantages of the tobacco plant platform for production on a huge scale. The start-up applies a proprietary protein extraction and purification technology that enables it to exploit nearly the entire plant, and at the same time deliver a high purity product at broad scale production. The company currently sources tobacco plants from local growers but the goal is to eventually source the raw material from tobacco growers globally. Based on cultivation in open fields and BioBetter’s proprietary purification technology, the cost of growth factors production is dramatically reduced, finally bringing cost efficiency to cultured meat production.
BioBetter was founded by Prof. Oded Shoseyov, a serial entrepreneur and researcher at The Hebrew University in Jerusalem; Dana Yarden MD, MBA, a biotech business expert; and Avi Tzur, an industrialist with an avid vision to put tobacco plant to positive use and who also was the first investor in the technology. One of the company’s first tobacco plant-based creations was the drug “Humira,” a monoclonal antibody used to treat autoimmune diseases. Realizing the great gap in the supply of GFs for the fast-growing cultivated food niche of the alt protein scene, the company shifted its focus to filling that gap.
“BioBetter is pioneering a novel protein expression platform to address the fast-growing demand for complex recombinant proteins,” notes Shoseyov. “Our GF technology will enable production of animal-free GFs at a scale of thousands of tons per year, and at a cost of US$1 per gram. This will alleviate one of the biggest bottlenecks in advancing cultured meat to mass production.” The start-up already raised US$5M for its growth factor production platform from private investors, including Institutional VC and Alpha Capital Anstalt. The company participates in the Israel Innovation Authority program and the Good Food Institute, which also helps support the company’s financing.